Kinase promiscuity can lower compound activity towards the desired target and induce adverse effects, both of which are undesirable characteristics for cancer therapeutics; however, it is noteworthy that the structure (CK146) presented here may have potential to be further modified into anti-parasite or antiviral drugs with a dual target-hitting PIK4CB and CHKA alike. This evidence concerns the gene PI4KB and cancer.